Their studies showed 63-83% inhibition of CETP activity and a 25-48% increase in HDL with doses varying from 25 to 400 mg (p < 0.05). Within the study, there were 13 adverse events, which varied from headache, hypertriglyceridemia, diarrhea, nausea, dizziness, periodontal disease, allergic rhinitis, and elevated CPK. This evidence concerns the gene PIK3C2A and hypertriglyceridemia.